<SEC-DOCUMENT>0001628280-25-008163.txt : 20250226
<SEC-HEADER>0001628280-25-008163.hdr.sgml : 20250226
<ACCEPTANCE-DATETIME>20250226161707
ACCESSION NUMBER:		0001628280-25-008163
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250226
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250226
DATE AS OF CHANGE:		20250226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		25670301

	BUSINESS ADDRESS:	
		STREET 1:		1800 OWENS STREET
		STREET 2:		SUITE 900
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		1800 OWENS STREET
		STREET 2:		SUITE 900
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vir-20250226.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfcc3edf-edcc-47b5-b947-50d9ae030b02,g:681388a4-c9bd-46fe-b380-adcb5e5a3e92,d:e7f5e61ada734df19dfad0ad7c264c1b-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vir-20250226</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001706431</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vir-20250226.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-26</xbrli:startDate><xbrli:endDate>2025-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNAS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-26</xbrli:startDate><xbrli:endDate>2025-02-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie7f5e61ada734df19dfad0ad7c264c1b_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February&#160;26, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Vir Biotechnology, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39083</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">81-2730369</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or Other Jurisdiction <br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer <br/>Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1800 Owens Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 900</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">California</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">94158</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">415</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">906-4324</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:38.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading <br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">VIR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie7f5e61ada734df19dfad0ad7c264c1b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;26, 2025, Vir Biotechnology, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter and full year ended December&#160;31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="ie7f5e61ada734df19dfad0ad7c264c1b_13"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20250226-q4ex991earningsr.htm">Press Release of the Company, dated February 26, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie7f5e61ada734df19dfad0ad7c264c1b_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIR BIOTECHNOLOGY, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 26, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jason O'Byrne</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jason O'Byrne, MBA<br/>Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20250226-q4ex991earningsr.htm
<DESCRIPTION>EX-99.1 EARNINGS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2bde0a06f6464fcea924998ea6129552_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div><img alt="virbiotechnologylogoa.jpg" src="virbiotechnologylogoa.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors, with potential for expanded therapeutic index </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Focused prioritization and disciplined capital deployment of $1.10 billion in cash, cash equivalents and investments enable cash runway into mid-2027 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Conference call scheduled for February&#160;26, 2025 at 1&#58;30 p.m. PT &#47; 4&#58;30 p.m. ET</font></div><div id="i2bde0a06f6464fcea924998ea6129552_4"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SAN FRANCISCO, February&#160;26, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Vir Biotechnology, Inc. (Nasdaq&#58; VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December&#160;31, 2024.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,&#8221; said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;As we enter 2025, we are poised for significant advancement with the initiation of our Phase 3 registrational program in chronic hepatitis delta and further clinical progression of our dual-masked T-cell engagers in solid tumors. Our disciplined capital deployment and strategic approach to partnerships enable us to maximize value creation from our pipeline and deliver transformative therapies to patients.&#8221; </font></div><div id="i2bde0a06f6464fcea924998ea6129552_7"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Pipeline Programs</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chronic Hepatitis Delta (CHD)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">ECLIPSE Phase 3 registrational clinical program in chronic hepatitis delta is advancing with the first patient in (FPI) expected during the first half of 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">Positive data from the SOLSTICE Phase 2 clinical trial were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in November 2024. This data demonstrated the potential of the first-of-its-kind investigational combination to address a critical unmet need in CHD, showing rapid and sustained virologic suppression, using the most stringent measure of zero detectable hepatitis delta RNA in the blood or target not detected, (TND defined as HDV RNA &#60; 0 IU&#47;mL), and no treatment-related serious adverse events (SAEs).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">Tobevibart and elebsiran combination therapy has received multiple regulatory designations potentially supporting an expedited development and review process and recognizing the significant unmet need in CHD&#58; U.S. FDA Breakthrough Therapy designation, U.S. FDA Fast Track designation, European Priority Medicines (PRIME) designation and European Orphan Drug designation.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solid Tumors</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In January 2025, the Company presented encouraging preliminary safety and efficacy data in ongoing Phase 1 dose escalation trials for its dual-masked T-cell engager (TCE) programs. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">VIR-5818, the only dual-masked HER2-targeting TCE in clinical trials, showed tumor shrinkage across various tumor types in 50% (10&#47;20) of participants receiving doses &#8805;400 &#181;g&#47;kg, with confirmed partial responses in 33% (2&#47;6) of participants with HER2-positive colorectal cancer (CRC).</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">VIR-5500, the only dual-masked PSMA-targeting TCE in clinical trials, showed PSA reductions in 100% (12&#47;12) of metastatic castration resistant prostate cancer (mCRPC) patients after an initial dose &#8805;120 &#181;g&#47;kg. PSA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> response was confirmed in 58% (7&#47;12) of participants.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">Both clinical candidates have shown promising safety profiles, with maximum tolerated dose (MTD) not yet reached, no dose-limiting cytokine release syndrome (CRS) observed and no CRS greater than grade 2.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Initial clinical data demonstrate the PRO-XTEN&#8482; masking technology&#8217;s potential to minimize systemic toxicity while enabling selective killing of cancer cells in the tumor microenvironment, minimizing CRS and expanding the therapeutic index compared to traditional therapeutic approaches. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">The Company is advancing VIR-5818 and VIR-5500 through ongoing Phase 1 dose escalation studies, aiming to further optimize dosing and efficacy. Additionally, the Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting TCE, in the first half of 2025, evaluating its potential across a number of solid tumor indications. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chronic Hepatitis B (CHB)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company anticipates functional cure data from the 24-week follow-up of the MARCH Part B Phase 2 trial in the second quarter of 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">Positive end-of-treatment results of the MARCH Part B Phase 2 trial evaluating tobevibart and elebsiran in combination with PEG-IFN&#945; or tobevibart and elebsiran alone were presented at AASLD The Liver Meeting&#174; in November 2024. The data demonstrated compelling hepatitis B surface antigen (HBsAg) loss and anti&#8211;hepatitis B surface antibody (anti-HBs) development at the end of treatment.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Future advancement in CHB by the Company will be contingent on securing a worldwide development and commercialization partner outside of China Territory (People&#8217;s Republic of China, Hong Kong, Taiwan and Macau) to best enable further development in this area of high unmet need. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preclinical Pipeline Candidates</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company is advancing multiple undisclosed dual-masked TCEs against clinically validated targets with potential applications across a variety of solid tumors. These preclinical candidates leverage the PRO-XTEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> masking technology with novel TCEs discovered and engineered using Vir Biotechnology&#8217;s antibody discovery platform and the Company&#8217;s proprietary dAIsY&#8482; (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">d</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ata </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AI s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tructure and antibod</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">y</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) AI engine.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">The Company continues to advance its HIV broadly neutralizing antibody program for HIV cure in collaboration with the Gates Foundation. </font></div><div id="i2bde0a06f6464fcea924998ea6129552_10"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Update</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">In November 2024, the Company hosted an investor event highlighting positive data from its SOLSTICE Phase 2 trial in hepatitis delta and its MARCH Part B Phase 2 trial in hepatitis B presented at AASLD.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">In January 2025, the Company announced positive initial Phase 1 dose escalation data for two of its PRO-XTEN&#8482; masked TCEs through an investor event. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.37pt">The Company announced Maninder Hora, Ph.D. will assume the role of Executive Vice President, Chief Technical Operations Officer in February 2025, following the departure of the current Chief Technology Officer, Aine Hanley, Ph.D.</font></div><div id="i2bde0a06f6464fcea924998ea6129552_13"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter and Full Year 2024 Financial Results</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Our focus on operational efficiency and program prioritization achieved a 28% year-over-year reduction in operating expense, excluding the upfront expense related to the Sanofi licensing agreement,&#34; said Jason O'Byrne, MBA, Executive Vice President and Chief Financial Officer, Vir Biotechnology. &#34;We enter 2025 with a robust financial position to support our key strategic priorities, including $1.10 billion in cash, cash equivalents and investments and a cash runway into mid-2027.&#34;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had approximately $1.10 billion in cash, cash equivalents and investments, representing a decline of approximately $90.6 million during the fourth quarter of 2024. For the full year of 2024, cash, cash equivalents and investments declined approximately $532.3 million. The 2024 full year decrease includes a $103.7 million upfront payment made to Sanofi upon the closing of the Sanofi license agreement and $75.0 million that was reclassified to restricted cash in the third quarter of 2024 and subject to VIR-5525 achieving &#8220;first in human dosing&#8221; by 2026. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue for the quarter ended December&#160;31, 2024 was $12.4 million compared to $16.8 million for the same period in 2023. Revenue for the full year of 2024 was $74.2 million compared to $86.2 million in 2023. The decreases in the fourth quarter and full year were primarily driven by grant revenue, where lower revenue was recognized in accordance with our agreement with BARDA and the Gates Foundation. In addition, the decrease in the full year 2024 was attributable to lower revenues from the release of profit-sharing amount previously constrained under the 2020 GSK Agreement, partially offset by the recognition of deferred revenue related to the expiry of GSK&#8217;s rights to select up to two additional non-influenza target pathogens during the first quarter of 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost of revenue for the fourth quarter of 2024 was $0.7 million compared to $0.8 million for the same period in 2023. Cost of revenue for the full year of 2024 was $0.8 million compared to $2.8 million in 2023. The decreases were due to lower third-party royalties owed based on the lower collaboration revenue under the 2020 GSK Agreement.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses (R&#38;D)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> R&#38;D expenses for the fourth quarter of 2024 were $106.1 million, which included $8.3 million of non-cash stock-based compensation expense, compared to $109.1 million for the same period in 2023, which included $16.5 million of non-cash stock-based compensation expense. R&#38;D expenses for the full year of 2024 were $506.5 million, which included $43.9 million of non-cash stock-based compensation expense, compared to $579.7 million in 2023, which included $62.7 million of non-cash stock-based compensation expense. The decrease of the fourth quarter R&#38;D expense was primarily due to lower expenses for personnel and de-prioritized programs, partially offset by non-cash in-process R&#38;D assets impairment charges and contingent consideration liability revaluation. The decrease of the full year R&#38;D expense was primarily due to lower clinical costs and contract manufacturing costs associated with the Company&#8217;s discontinued flu asset, VIR-2482, lower contract manufacturing costs associated with elebsiran used in the Company&#8217;s CHD and CHB clinical trials and lower personnel costs, partially offset by the $102.8 million of the Sanofi upfront payment being recognized as in-process R&#38;D expense.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses (SG&#38;A)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SG&#38;A expenses for the fourth quarter of 2024 were $26.7 million, which included $7.5 million of non-cash stock-based compensation expense, compared to $41.2 million for the same period in 2023, which included $11.8 million of non-cash stock-based compensation expense. SG&#38;A expenses for the full year of 2024 were $119.0 million, which included $34.5 million of non-cash stock-based compensation expense, compared to $174.4 million in 2023, which included $48.6 million of non-cash stock-based compensation expense. The decrease in both the fourth quarter and the full year was primarily related to lower personnel and other expenses associated with previously announced cost-saving initiatives.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring, Long-Lived Assets Impairment and Related Charges&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restructuring, long-lived assets impairment and related charges for the fourth quarter of 2024 were $(3.9) million compared to $4.7 million for the same period in 2023. The $(3.9) million in the fourth quarter of 2024 was primarily related to a gain from terminating our lease in St. Louis, Missouri. The $4.7 million in the fourth quarter of 2023 was primarily related to the severance expenses. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Income&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income for the fourth quarter of 2024 was $12.5 million compared to $18.3 million for the same period in 2023. The decrease was primarily due to lower interest income. Other income for the full year of 2024 was $64.1 million compared to $56.1 million in 2023. The increase was primarily due to lower unrealized loss from the Company's equity investment and lower foreign exchange loss, partially offset by lower interest income.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Benefit from Income Taxes&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Benefit from income taxes for the fourth quarter and the full year of 2024 was nominal. Benefit from income taxes for the fourth quarter and the full year of 2023 was $4.8 million and $13.1 million, respectively, primarily due to a pre-tax loss and the Company&#8217;s ability to carry back the research and development credit to 2022.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss attributable to Vir Biotechnology for the fourth quarter of 2024 was $(104.6) million, or $(0.76) per share, basic and diluted, compared to a net loss of $(116.0) million, or $(0.86) per share, basic and diluted, for the same period in 2023. Net loss attributable to Vir Biotechnology for the year of 2024 was $(522.0) million, or $(3.83) per share, basic and diluted, compared to a net loss of $(615.1) million, or $(4.59) per share, basic and diluted, in 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="i2bde0a06f6464fcea924998ea6129552_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Financial Guidance</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund its operations into mid-2027.</font></div><div id="i2bde0a06f6464fcea924998ea6129552_19"></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call</font></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vir Biotechnology will host a conference call to discuss the fourth quarter and full year 2024 results at </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1&#58;30 p.m. PT &#47; 4&#58;30 p.m. ET today.</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> A live webcast will be available on&#160;</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;investors.vir.bio&#47;</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and will be archived&#160;for 30 days.</font></div><div id="i2bde0a06f6464fcea924998ea6129552_22"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About VIR-5818, VIR-5500, VIR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5525</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">VIR-5818, VIR-5500, VIR-5525 are investigational, clinical candidates currently being evaluated for the treatment of solid tumors. These assets leverage the PRO-XTEN&#8482; masking technology with three different T-cell engagers (TCEs) targeting HER2, PSMA, and EGFR, respectively.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TCEs are powerful anti-tumor agents that can direct the immune system, specifically T-cells, to destroy cancer cells. The PRO-XTEN&#8482; masking technology is designed to keep the TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, leading to killing of cancer cells. By driving the activity exclusively to the tumor microenvironment, we aim to circumvent the traditionally high toxicity associated with TCEs and increase their efficacy and tolerability. Additionally, the mask is designed to help drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing less frequent dosing regimens for patients and clinicians.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Tobevibart and Elebsiran</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood.  Tobevibart was identified using Vir Biotechnology&#8217;s proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and&#8239;clearance of HBsAg immune complexes and incorporates Xencor&#8217;s Xtend&#8482; technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta and patients with chronic hepatitis B. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta and patients with chronic hepatitis B.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Vir Biotechnology, Inc.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vir Biotechnology has exclusive rights to the PRO-XTEN&#8482; masking platform for oncology and infectious disease. PRO-XTEN&#8482; is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><div id="i2bde0a06f6464fcea924998ea6129552_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;aim,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;promising&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding&#58; Vir Biotechnology&#8217;s cash balance and anticipated runway&#59; Vir Biotechnology&#8217;s future financial and operating results and its expectations related thereto, including Vir Biotechnology&#8217;s financial guidance&#59; the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">therapeutic potential of Vir Biotechnology's CHD and CHB programs, as well as Vir Biotechnology's strategy, plans and expectations related thereto&#59; the therapeutic potential of Vir Biotechnology's oncology solid tumor portfolio, preclinical pipeline and PRO-XTEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> masked TCE platform, as well as Vir Biotechnology's strategy, plans and expectations related thereto&#59; the potential of and Vir Biotechnology&#8217;s expectations for its other pipeline programs&#59; Vir Biotechnology&#8217;s clinical development plans and expectations for its oncology and hepatitis programs, including protocols for and enrollment into ongoing and planned clinical studies, potential partnering opportunities, and data readouts and presentations, as well as anticipated timelines&#59; the potential benefits, safety and efficacy of Vir Biotechnology&#8217;s investigational therapies&#59; Vir Biotechnology&#8217;s strategy and plans&#59; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation&#58; unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events&#59; risks of unexpected costs, delays or other unexpected hurdles&#59; the timing and amount of Vir Biotechnology&#8217;s actual operating expenses, as determined in accordance with U.S. Generally Accepted Accounting Principles&#59; difficulties in collaborating with other companies, some of whom may be competitors of Vir Biotechnology or otherwise have divergent interests, and uncertainty as to whether the benefits of Vir Biotechnology&#8217;s various collaborations can ultimately be achieved&#59; challenges in accessing manufacturing capacity&#59; clinical site activation rates or clinical enrollment rates that are lower than expected&#59; the timing and outcome of Vir Biotechnology&#8217;s planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals&#59; successful development and&#47;or commercialization of alternative product candidates by Vir Biotechnology&#8217;s competitors, as well as changes in expected or existing competition&#59; Vir Biotechnology&#8217;s use of artificial intelligence and machine learning in its efforts to engineer next-generation proteins and in other research and development efforts&#59; geopolitical changes or other external factors&#59; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology&#8217;s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology&#8217;s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology&#8217;s filings with the U.S. Securities and Exchange Commission, including the section titled &#8220;Risk Factors&#8221; contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><div id="i2bde0a06f6464fcea924998ea6129552_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">VIR BIOTECHNOLOGY, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Consolidated Balance Sheets </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">(in thousands, except share and per share data)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">(unaudited)</font></div><div><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CURRENT ASSETS&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">222,947&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">241,576&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">678,051&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,270,980&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Restricted cash and cash equivalents, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">89,385&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">13,268&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Equity investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4,350&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">9,853&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">47,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">52,549&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,042,458&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,588,226&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">8,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">22,565&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">16,937&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">16,937&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">63,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">96,018&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">59,680&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">71,182&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Restricted cash and cash equivalents, noncurrent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6,363&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Long-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">190,015&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">105,275&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12,409&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">TOTAL ASSETS</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,398,813&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,919,060&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CURRENT LIABILITIES&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">5,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6,334&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accrued and other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">85,873&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">104,220&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred revenue, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12,648&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">64,853&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Contingent consideration obligation, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">16,060&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">119,662&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">175,407&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating lease liabilities, noncurrent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">90,139&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">111,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Contingent consideration obligation, noncurrent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">24,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">25,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">14,577&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">15,784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">TOTAL LIABILITIES</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">248,428&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">328,824&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">STOCKHOLDERS&#8217; EQUITY&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Preferred stock, $0.0001 par value&#59; 10,000,000 shares authorized as of December&#160;31, 2024 and 2023, respectively&#59; no shares issued and outstanding as of December&#160;31, 2024 and 2023</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock, $0.0001 par value&#59; 300,000,000 shares authorized as of December&#160;31, 2024 and 2023, respectively&#59; 136,959,446 and 134,781,286 shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,911,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,828,862&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(1,717)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(815)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(759,784)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(237,824)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">TOTAL STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,150,385&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,590,236&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,398,813&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1,919,060&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">VIR BIOTECHNOLOGY, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">in thousands, except share and per share data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">(unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Collaboration revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,413&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,858&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,266&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Contract revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">744&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,333&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Grant revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,185&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,493&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,686&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,374&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,787&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,205&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,180&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cost of revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,083&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579,720&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,031&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Restructuring, long-lived assets impairment and related charges</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,944)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,699&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,995&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,559&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,524&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,803&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">661,370&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770,485&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117,150)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139,016)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(587,165)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(684,305)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change in fair value of equity investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,172)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(992)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,528)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,888)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,153&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,809&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,990&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,485)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,221)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,991)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total other income</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,475&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,259&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,060&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,111&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Loss before benefit from income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104,675)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120,757)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(523,105)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(628,194)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Benefit from income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,784&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,145&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,077&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104,589)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115,973)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521,960)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(615,117)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss attributable to VirBio</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104,589)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115,973)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521,960)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(615,061)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss per share attributable to VirBio, basic</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.76)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.86)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.83)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.59)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss per share attributable to VirBio, diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.76)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.86)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.83)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.59)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Weighted-average shares outstanding, basic</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,808,690</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,608,811</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,246,865</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,130,924</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Weighted-average shares outstanding, diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,808,690</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,608,811</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,246,865</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,130,924</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i2bde0a06f6464fcea924998ea6129552_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arran Attridge</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Senior Vice President, Corporate Communications</font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">aattridge&#64;vir.bio</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Richard Lepke</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Senior Director, Investor Relations</font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">rlepke&#64;vir.bio</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vir-20250226.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfcc3edf-edcc-47b5-b947-50d9ae030b02,g:681388a4-c9bd-46fe-b380-adcb5e5a3e92-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vir="http://www.vir.bio/20250226" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vir.bio/20250226">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20250226_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20250226_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20250226_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vir.bio/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>vir-20250226_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfcc3edf-edcc-47b5-b947-50d9ae030b02,g:681388a4-c9bd-46fe-b380-adcb5e5a3e92-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vir.bio/role/Cover" xlink:type="simple" xlink:href="vir-20250226.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.vir.bio/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:to="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_290cad92-6e1a-4884-8f91-5290a852be1f_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:to="loc_dei_ExchangeDomain_290cad92-6e1a-4884-8f91-5290a852be1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:to="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNAS_0c959d36-1b02-4e4e-a01b-50bc2db33a5a" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNAS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:to="loc_exch_XNAS_0c959d36-1b02-4e4e-a01b-50bc2db33a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9ddeb086-abea-477f-82b7-ea464e4be39b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_DocumentType_9ddeb086-abea-477f-82b7-ea464e4be39b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c8b0927d-6ac5-4510-8a93-8bc4ee44fba1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_DocumentPeriodEndDate_c8b0927d-6ac5-4510-8a93-8bc4ee44fba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_89640ff1-41f5-41bb-97e5-f3b6bf49f9e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityRegistrantName_89640ff1-41f5-41bb-97e5-f3b6bf49f9e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a72bcd93-52c9-4e57-9850-9fa10760a3e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a72bcd93-52c9-4e57-9850-9fa10760a3e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7745f32e-559e-4012-976f-516c8d74cb93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityFileNumber_7745f32e-559e-4012-976f-516c8d74cb93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_54a1e2a5-7f52-4259-b530-dce23af3a128" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityTaxIdentificationNumber_54a1e2a5-7f52-4259-b530-dce23af3a128" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_59e6ae0e-5230-45c6-a1b9-5019f89b26fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressAddressLine1_59e6ae0e-5230-45c6-a1b9-5019f89b26fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_30381a8d-a088-44c5-a71f-0305896bb386" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressAddressLine2_30381a8d-a088-44c5-a71f-0305896bb386" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_14872192-ef73-4322-bc7b-7534d4768091" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressCityOrTown_14872192-ef73-4322-bc7b-7534d4768091" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7841ac6d-fabd-4c6c-9b8f-0c1aba06b55e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressStateOrProvince_7841ac6d-fabd-4c6c-9b8f-0c1aba06b55e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f82a3586-c4ca-464a-a8c8-0bbd45f82aa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressPostalZipCode_f82a3586-c4ca-464a-a8c8-0bbd45f82aa8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f896c0d3-b725-4097-804a-169ac0cc79ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_CityAreaCode_f896c0d3-b725-4097-804a-169ac0cc79ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_04d76a7c-4012-46ee-b40f-bcf3a30011e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_LocalPhoneNumber_04d76a7c-4012-46ee-b40f-bcf3a30011e7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_84a4a53d-b37d-476e-91c5-fe47930030d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_WrittenCommunications_84a4a53d-b37d-476e-91c5-fe47930030d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_28cf1265-2df3-46bc-a2e2-0ab5efc4bc37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_SolicitingMaterial_28cf1265-2df3-46bc-a2e2-0ab5efc4bc37" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ddc7b7b9-80dc-4232-bbd3-9923ddf093b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_PreCommencementTenderOffer_ddc7b7b9-80dc-4232-bbd3-9923ddf093b4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cde79afb-275e-4c22-9b4d-056d3ac5ac5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cde79afb-275e-4c22-9b4d-056d3ac5ac5b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_29e2e7b3-253c-4289-abf6-a68657845493" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_Security12bTitle_29e2e7b3-253c-4289-abf6-a68657845493" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_371f5a74-22b6-4298-ac39-72e3ce1b5cfe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_TradingSymbol_371f5a74-22b6-4298-ac39-72e3ce1b5cfe" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_841c5134-6533-4233-ad1c-7bd261adaf47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_SecurityExchangeName_841c5134-6533-4233-ad1c-7bd261adaf47" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e5c1f4e3-4550-4d7c-88f1-44dba98880fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityEmergingGrowthCompany_e5c1f4e3-4550-4d7c-88f1-44dba98880fb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7b15f33-ebbd-4555-a6a4-c7db278e5aad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_AmendmentFlag_e7b15f33-ebbd-4555-a6a4-c7db278e5aad" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6f3965dd-58d3-4f7a-941b-eb1e1d43937b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityCentralIndexKey_6f3965dd-58d3-4f7a-941b-eb1e1d43937b" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>vir-20250226_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfcc3edf-edcc-47b5-b947-50d9ae030b02,g:681388a4-c9bd-46fe-b380-adcb5e5a3e92-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_22a0cacd-b2eb-48a7-8cee-a3e151ab505a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_61317f4c-9f98-4d9b-b66d-13e05782b23b_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a5775b54-ddad-463b-84dd-a7b04431a082_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_86f3c655-1bc6-408a-ae2e-3fff64b1e2b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_decd3744-f432-4a65-82e7-dc8474408cd1_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_62986b03-2b04-43af-8128-aaf864753e49_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b47306ac-d40c-4057-ba9a-bcc810307ff5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1fbb22c4-b004-48de-b32a-0e70ef175269_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9db2e79d-643b-4eac-b7f1-61349f8e1c94_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6d60de9e-bfa7-41b7-b9f6-102b23fe327c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_fae2452f-b0ac-48d4-bbe3-418540c82dab_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ee34cce6-0225-4caa-a651-549dedeb41c6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4ceeb653-a85d-444e-b4ad-48e0b9b7ea3e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_964c4717-9777-49d7-b8aa-828cb88e8082_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_763e6e63-f0b5-4b0e-98ec-bdb7ff503245_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_22c227a7-d07b-4f38-89be-c6daa518e4f4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c94a0196-d985-4936-827c-ff5df7f847c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c8f2b689-c54e-4276-ab9c-7ae075e5708f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_e32bc8c4-0e55-4634-9f9d-28526029bf61_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b5ae61d1-d3f2-46ed-8535-a9611cad3459_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e1745324-1c1d-4c3c-af38-5c0aad1f66e4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3dacd803-a4f8-4dc8-ae63-eed6f211285c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ad3c5aff-1625-4c36-9d10-6a279f546fc2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_ee744ddc-6a56-4c0c-bde9-1e0da0906282_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9980df29-3d57-473c-9077-ad7e8a34d496_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f7c318d0-6ed4-484f-b58f-7560dce06a05_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNAS_83d4dda3-8d6d-4d17-83b0-cfef9f84af98_terseLabel_en-US" xlink:label="lab_exch_XNAS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ - ALL MARKETS</link:label>
    <link:label id="lab_exch_XNAS_label_en-US" xlink:label="lab_exch_XNAS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ - ALL MARKETS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNAS" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNAS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNAS" xlink:to="lab_exch_XNAS" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c0204abb-f96f-4165-97a5-3d5c7389ffdb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vir-20250226_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfcc3edf-edcc-47b5-b947-50d9ae030b02,g:681388a4-c9bd-46fe-b380-adcb5e5a3e92-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vir.bio/role/Cover" xlink:type="simple" xlink:href="vir-20250226.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vir.bio/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_84db5744-a862-42ff-a850-d1694e5661fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_84db5744-a862-42ff-a850-d1694e5661fe" xlink:to="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:to="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_290cad92-6e1a-4884-8f91-5290a852be1f" xlink:to="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNAS_0c959d36-1b02-4e4e-a01b-50bc2db33a5a" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNAS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_29483a0c-2055-4019-ac11-f284073aaefb" xlink:to="loc_exch_XNAS_0c959d36-1b02-4e4e-a01b-50bc2db33a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_98fe364b-eb19-4fe5-a1a2-71fafa4afadf" xlink:to="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9ddeb086-abea-477f-82b7-ea464e4be39b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_DocumentType_9ddeb086-abea-477f-82b7-ea464e4be39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c8b0927d-6ac5-4510-8a93-8bc4ee44fba1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_DocumentPeriodEndDate_c8b0927d-6ac5-4510-8a93-8bc4ee44fba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_89640ff1-41f5-41bb-97e5-f3b6bf49f9e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityRegistrantName_89640ff1-41f5-41bb-97e5-f3b6bf49f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a72bcd93-52c9-4e57-9850-9fa10760a3e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a72bcd93-52c9-4e57-9850-9fa10760a3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7745f32e-559e-4012-976f-516c8d74cb93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityFileNumber_7745f32e-559e-4012-976f-516c8d74cb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_54a1e2a5-7f52-4259-b530-dce23af3a128" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityTaxIdentificationNumber_54a1e2a5-7f52-4259-b530-dce23af3a128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_59e6ae0e-5230-45c6-a1b9-5019f89b26fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressAddressLine1_59e6ae0e-5230-45c6-a1b9-5019f89b26fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_30381a8d-a088-44c5-a71f-0305896bb386" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressAddressLine2_30381a8d-a088-44c5-a71f-0305896bb386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_14872192-ef73-4322-bc7b-7534d4768091" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressCityOrTown_14872192-ef73-4322-bc7b-7534d4768091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7841ac6d-fabd-4c6c-9b8f-0c1aba06b55e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressStateOrProvince_7841ac6d-fabd-4c6c-9b8f-0c1aba06b55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f82a3586-c4ca-464a-a8c8-0bbd45f82aa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityAddressPostalZipCode_f82a3586-c4ca-464a-a8c8-0bbd45f82aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f896c0d3-b725-4097-804a-169ac0cc79ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_CityAreaCode_f896c0d3-b725-4097-804a-169ac0cc79ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_04d76a7c-4012-46ee-b40f-bcf3a30011e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_LocalPhoneNumber_04d76a7c-4012-46ee-b40f-bcf3a30011e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_84a4a53d-b37d-476e-91c5-fe47930030d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_WrittenCommunications_84a4a53d-b37d-476e-91c5-fe47930030d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_28cf1265-2df3-46bc-a2e2-0ab5efc4bc37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_SolicitingMaterial_28cf1265-2df3-46bc-a2e2-0ab5efc4bc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ddc7b7b9-80dc-4232-bbd3-9923ddf093b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_PreCommencementTenderOffer_ddc7b7b9-80dc-4232-bbd3-9923ddf093b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cde79afb-275e-4c22-9b4d-056d3ac5ac5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cde79afb-275e-4c22-9b4d-056d3ac5ac5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_29e2e7b3-253c-4289-abf6-a68657845493" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_Security12bTitle_29e2e7b3-253c-4289-abf6-a68657845493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_371f5a74-22b6-4298-ac39-72e3ce1b5cfe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_TradingSymbol_371f5a74-22b6-4298-ac39-72e3ce1b5cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_841c5134-6533-4233-ad1c-7bd261adaf47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_SecurityExchangeName_841c5134-6533-4233-ad1c-7bd261adaf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e5c1f4e3-4550-4d7c-88f1-44dba98880fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityEmergingGrowthCompany_e5c1f4e3-4550-4d7c-88f1-44dba98880fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7b15f33-ebbd-4555-a6a4-c7db278e5aad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_AmendmentFlag_e7b15f33-ebbd-4555-a6a4-c7db278e5aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6f3965dd-58d3-4f7a-941b-eb1e1d43937b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f5a3ab37-5052-4296-938f-8f403609462e" xlink:to="loc_dei_EntityCentralIndexKey_6f3965dd-58d3-4f7a-941b-eb1e1d43937b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>virbiotechnologylogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 virbiotechnologylogoa.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +."_$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBOFS]ICXX>(O@U\0O#,NE/'<Z=<6
M;M=:=<#]W-B3&0>JMCHP_$$<4 ?2=%><_"/X[^&?C#8 Z9<?9-5C7=/I=R0)
MH_4K_?7_ &AZC(!XKT:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *^*OV^/^1N\*_]>,O_ *,K[5KXJ_;X_P"1N\*_]>,O_HR@
M3/F/3=2N]'OH+VQN9K.\@;?%<0.4=&]0PY!K[ ^!O[9D-\;?1/'[I;W!PD6N
M(NV-ST'G*.%/^V/E]0.37QK10(_7>">.ZACFAD66&10Z21L"K*1D$$=014E?
MG-\$?VE/$'PAN(K*4MK'AIF_>:?(_P T6>K0L?NGOM^Z>>A.1]Y?#_XD:!\3
MM!35O#]\MW!P)8F^66!O[DB]5/Z'J"1S0,Z>BBB@84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7Q5^WQ_R-WA7_KQE_P#1E?:M?%7[?'_(W>%?
M^O&7_P!&4"9\LT444$A71^!?'^N_#?7HM7T"^>RNT^5@.8Y4SRCKT93_ /7&
M#@USE% 'Z,_ O]I'1/C!;)93;-)\3(F9-/=OEFP.6A)^\.^WJ/<<U[%7Y%V=
MY/I]U#=6LTEM<PN)(YHF*NC Y!!'((-?9O[/?[74.O&U\.^.)X[;4CB.VUAL
M+'.>@67LK?[70]\'J%7/J>BD!R,CD4M PHHHH **** "BBB@ HHKYA_:S_:(
MG\'H_@WPU<^3K$T>;^\C/S6L;#A$/9V!SG^$$8Y.0 =5\9OVL/#OPQGGTK3$
M'B'Q!&2LD$,FV"W;TD?GY@?X5YX()6ODWQE^T[\1?&DS^;X@FTFV8\6NDDVR
MJ/3<IWD?[S&O*_O9).324$FC<>(-5NI6EGU.\FE;J\D[L3^)-:FA_$GQ9X9E
M632O$FJV!7^&&\D"GO@KG!'L17-44"/IOX:_MO>(=%FBM?&%I'KUAG#7ELBP
MW2#UP,(_TPI]Z^P?!?CK0_B'H<6K:!J$>H63\$IPT;=U=3RK>Q^O2ORCKM?A
M1\5M:^$?BB'5M*E9H20MW9,Q$=S'GE6'8]<-U!_$$'<_4:BL+P/XRTWX@>%M
M/U_29?-LKR/>H/WD;HR-Z,I!!^E;M!04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5:9XV\/V6M:/=+=Z?=QB2.1>ONI'9@<@@]"#6O04%%%% 'S/^WA:O)\-M!N
MK%(]6",03@;H9,9'_ >O^-?#E?I7^TKX+D\=?!O7[*WC,M[;1B^MU49):([B
M .Y*;U'NU?FI02PHHHH$%%%% !1110!O> K62^\=>'+:(9EFU*VC0<\L95 Z
M?6OU=K\ZOV2_!<GB[XSZ5.4W6>CAM1F8C@%>(Q]?,9#] :_16@I!1110,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXC_]"%?1%?U!X/\ ^Z8S_%'\F?#\1?Q*?HPHHHK^@SY **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M17SOH7_(<T__ *^(_P#T(5]$5_4'@_\ [IC/\4?R9\/Q%_$I^C"BBBOZ#/D
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^)?@]J8AU>V\[3I6VVVIVX)@F]L_PM@'Y3SP<9'-!)Y]1110(**** "BBB@
MK[C^!FA'PW'X5TYE*2PJIE4G.)&!9Q_WTQKY+^%7AG_A*O'&G6SIOMH6^TW
M(R-B$'!'H3M7_@5?9W@]BOBG2R.#]H0?K7X-XAYM%9KEF60>U2-27_@24?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^ANN?\ P'A_^(H_X:@^*/\ T-US_P" \/\ \11_PR_\4?\ H4;G_P "(?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M27##@>P]36SX+^'<NM;+S40T%CU6/H\O^"^_Y>M>LVUK%9P)!!&L4,8PJ(,
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MDX[X5B1[@4#/U%HIJL)%#*0RD9!!X-.H*"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _)SQE_R-VN?]?T__ *,:L>MCQE_R
M-VN?]?T__HQJQZ" HHHH _33]G/_ )(?X._Z\5_]"->CUYQ^SG_R0_P=_P!>
M*_\ H1KT>@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBO'_CA=#A:QLW!U"1
M>67_ )8J>_\ O>GY^F9/''CJ/P_"UI9LLNHL,>HA'J??T'X_7QV::2XF>65V
MDD<[F9CDDGN:_!^/N.XY?&>597.]9Z2DOL>2_O?^D^NWU64Y4ZS5>NO=Z+O_
M ,#\QK,68LQ)).23WI***_E4^]"K6E_\A*T_Z[)_Z$*JU:TO_D)6G_79/_0A
M71AOX]/U7YD5/@9]&4445_HT?C9\F?M^*/[+\%M@;A-= ''/*Q?X#\J^/K.[
MFT^ZAN;>1H9X7$D<B]58'(-?8?[?:G^Q_!K8.T7%R"<<?=C_ ,#7QK2:4DTU
MHQ;.Z/KCX:>/(/'N@QS JFHPX2Z@'9O[P']T]OQ':O>O _PY$?EW^KQ9?[T=
MJPX'N_\ A^?I7YY_#OQ]J7PT\666NZ84>:W;+P3#,<R=U8?R/4'!'(K]*/AC
M\3=%^*WA>#6M&FRK?+/;.1YEO)CE''KZ'H1R*_(\O\-LKP6:U,PG[].]X4VM
M(OK?^:S^%=%O=GT-7.J]6@J*T?5]_P#+S.LI:**_73Y\**** "BBB@ HHHH
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M%% !1110 4444 %%%% !7YQ_M;?\G!^*O^W3_P!)(:_1ROSC_:V_Y.#\5?\
M;I_Z20T"9Y!11102%?</[!O_ "3GQ!_V%3_Z)CKX>K[A_8-_Y)SX@_["I_\
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M* "BBB@ HHHH K:A?V^E:?<WMU((;6VB::60@D*B@ECQZ &O-?\ AJ+X7?\
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M_P#H1KT>O./V<_\ DA_@[_KQ7_T(UZ/06%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-\ _%GQ:\8:3J/A^&UDMK:P^SR&XN!&=_F.W /;!%>+?\,7?$O\ Y]=-_P#
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M+=!&($:*<C''(-<-_P ,7?$O_GUTW_P-'^%?H)10*Q^??_#%WQ+_ .?73?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9GCT^W;']WYY/PYC_(T#/K:BBB@H**** "BBB@ HHHH **** "BBB@ HHHH
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MH;'QE;?V[8#Y?MUN%2[0>I'"R?\ CI[DFOK?P'\3O#'Q*T_[7X=U>#4 HS)
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M8Y*1](U_X"@4?A7W9^UQX[_X0OX/:A;0R;+[6F&G18Z[&!,I^FP,OU<5^=U
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M*5^F-V*QY_$&JW3;YM2O)7QC=).[']37LUG^Q;\2KK'FVVFV>?\ GM>J<?\
M? :M2']A?X@2Q[FU+P]"?[CW4Q/Z0D4 >'6GC3Q#8;?LNNZG;;1@>3>2+@>@
MPU>A?#'XX>/X_&_AZR;Q=JUS:W&HV\,L5W<M.&1I%5A\^>Q-=E_PPCX^_P"@
MOX;_ / FX_\ C%7_  G^QCX\\/>,M%U">ZT66UL;Z"XD:&ZD)*I(K' ,8YP#
MUH ^WJ***"@HHHH **** "BBB@ HHHH *_./]K;_ ).#\5?]NG_I)#7Z.5^<
M?[6W_)P?BK_MT_\ 22&@3/(****"0K[A_8-_Y)SX@_["I_\ 1,=?#U?</[!O
M_).?$'_85/\ Z)CH&CZ:HHHH*"BBB@ HHHH **** "BBFLPC4LQ"J!DDG@4
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M(^]OV(=2N]4^%&K2WEU->2KK<JB2>0NP'D0'&2>G)_.OH6OG']A'_DD6K_\
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M:O\ Q!J4^H:G>37]].VZ2XN)"[L?<F@5SZ5^('[=&MZDTMOX1TJ'1[?HMY?
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M10,**** "BBB@ HHKYR^/O[6ECX!DN-!\*>3JOB!"8YKICNM[-NXX^^X_N]
M>O(*T >U^-/B#X=^'FFF^\0ZM;Z9!SL$K9DD([(@RS'Z U\P>/\ ]NZ1FDMO
M!NAJJY(%_JW)/NL2GCV)8^XKY:\2>*-6\8:M-JFMZA<:G?S?>FN'+'Z#L .P
M& .PK*H)N>@>*OCY\0?&3/\ VEXIU 1-UM[23[-%CT*Q[01]<UP4DC2NSNQ=
MV.2S')-+##)<3)%$C2RR,%2- 2S$G   ZFOH#X>?L7>,?%D,5WKDT/A:RD 8
M)<(9;D@_],@1M^C,"/2@#Y[HK[PT;]AKP)8Q@W]_K&IRX^;=.D2?@%3(_P"^
MC6Y)^QO\,9(=BZ7>1MQ^\6^EW?J2/TH"Q^>=6+*^N=-N%N+2XEM9U^[+"Y1A
M]".:^VO$7["/A.]B8Z-KFJ:7.>GVC9<Q#T^7"M_X]7S]\4/V6_&OPSAEO3;)
MKFCQC<U[IV6\M?62,C<ON1E1ZT 5/"'[3WQ'\'-&(O$,VJ6R?\N^JC[2K#TW
M-\X'T85]"_#O]N30M8:.U\7Z;)H4YX-[:;I[<GU*XWI^&[ZU\244 ?K;HNN:
M?XBTV'4-+O;?4+*892XMI Z-^(J]7Y9_#GXK>)?A7JPOO#^H/;JQ!FM9/F@G
M [.G0_48([$5]Z? _P#:&T+XRV(@7&F>(H4W3Z;(V=P'5XC_ !+^HSSV)!GK
M%%%% PHHHH **** /R<\9?\ (W:Y_P!?T_\ Z,:L>MCQE_R-VN?]?T__ *,:
ML>@@**** /TT_9S_ .2'^#O^O%?_ $(UZ/7G'[.?_)#_  =_UXK_ .A&O1Z"
MPHHHH **** "F22+#&SNRHBC<S,<  =237,?$;XF:#\*_#\FKZ]=^1%RL,$8
MW37#X^Y&O<_H.I(%?!'QD_:0\3_%RXEMFE;2/#^[Y-+MG.&'8RMP9#_X[Z#O
M0(^J/B5^V)X,\$/+9Z06\4ZDF1MLG"VRMZ--R#_P -^%?-OC/]L+XA^*GD2S
MO8?#MHQP(M.B ?'O(V6S[KM^E>'T4"-/6O$FK^))S-JVJ7NJ39SYEY</*V?J
MQ-9E=S\-O@QXM^*UT8] TQI+56VRW]P?+MXOJYZGV4$^U?2?A/\ 8+TV&-'\
M2^);JYE(RT.EQK$JGTWN&+#_ ("* /C.BOT(L_V,OAG;+B2PO[LXQNFOG!^O
MR[:J:I^Q-\.;Y&%O_:VG,>C6]X&Q_P!]JW^30%CX"KJ?#/Q1\7>#60Z+XCU+
M3T3I#'<,8OQC)*G\17T!XX_83U:QCDN/"NN0ZH!R+._3R9?H'&58_4**^:_$
MGA?5O!^KS:7K>GSZ;J$/WX+A-IQV([$'L1P>QH ^A? W[<WB;26CA\3Z9:Z]
M;]&N+?\ T:X^O'R'Z!5^M?3_ ,,_COX.^*R!-%U,)J&W<VFW@\JX7UPN<,!Z
MJ2*_,:I;>XEM9HYH9'AFC8,DD;%64CD$$=#0%S]=J*^+_@7^V1=Z9+;:)X]E
M:\L3A(]:P3-%Z><!]]?]H#=Z[NWV59WD&H6L-U:S1W%M,@DBFB8,CJ1D,"."
M".]!1-1110 4444 %%%% !117G7QF^-VA_!G0OM6H-]KU.<$6>FQ,!),?4_W
M4!ZMCZ GB@#MM;U[3O#>FS:CJM];Z=8PC,EQ<R!$7\3W]N]?,WQ)_;DTS2Y)
M;/P7IG]KRKD?VC?[HX,^JQ\.P^I2OF'XG?%[Q+\6M7-YKMZ6A1B;>QARMO;C
MT5<]?]HY)]:XJ@FYZ/XP_:'^(7C9I!?^);R"V<G_ $6P;[-$!_=(3!8?[Q->
M=R2/-(TDC,[L<LS'))]2:910(**[CP5\$_&_Q"5)=#\.7ES:OTNY5$,!'J)'
M(4_@2:]:T?\ 85\:WB!]0U;1].!_@6229Q]<(!^1- SYMJS8ZA=:7<+/9W,U
MI.O26"0HP_$5]4+^P'J&T9\96H/?%@Q_]J5'<_L"ZNL>;?Q?92O_ '9+-T'Y
MAC_*@#RGPC^U!\2/![((O$,NJ6Z];?5A]I5O8LWSC\&%?1/PW_;@T'79(K/Q
M;8-X?N6X^VVY,UL3[C&Y/_'AZD5Y#K7[$?Q#TU6:TDTG5AV6VNBC'_OXJC]:
M\O\ %7P=\;>"@[:SX8U&TA3[UP(3)"/^VB97]: U/HW]MSQ<TVG^ +[0-99K
M*Z6^9;C3KH^7*!]GP=R'!QD_K7RQ_P )EK__ $'-1_\  N3_ !K,:XE:%(6D
M<PHS,L98[58X!('8G:,_05%0!L?\)EK_ /T'-1_\"Y/\:/\ A,M?_P"@YJ/_
M (%R?XUCT4"/N#]A?5KW5O"GB=[V\N+QDO8PK7$K.0/+Z#)KZ;KY9_8'_P"1
M1\4_]?T7_HNOJ:@LS_$&BP^(]#O]+N&D2"\@>!WA8JZA@1N4CH1U!]17YB>,
M+CQ7X)\4:IH6H:SJ2WEA.T#_ .E2 -@\,.>A&"/8BOU+KXY_;F^&?V>]TSQQ
M90?)/BQU!E'\8'[IS]5!4G_90=Z!,^8O^$RU_P#Z#FH_^!<G^-'_  F6O_\
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MX^JYOIV7HME\C[3#X6CA8\E*-@HHHKQ#J"BBB@ HHHH **** "BBB@ HHHH
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MG\Q[K7TU97UMJ=G#=V=Q%=VLRAXYX'#HZGH58<$?2@HGHHHH **** "BBB@
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M%_Z)CKRN@@**** /NW]A'_DD6K_]AR;_ -)[>OHZOG']A'_DD6K_ /8<F_\
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MC/\ :#_9#CT.QNO$G@:.5[6$&6ZT8DNT:CDO"3R0.I4Y/7![5\H5^O=?G?\
MM8?"V+X;_$M[C3X1#H^M*;RWC086*3.)8Q[!B& '0.!VH)9XI1110(TO#OB"
M_P#"NN66KZ7<-:ZA9RB:&5>S#U]0>A'<$BOT]^%WQ M/B=X%TOQ%9@(+J/$T
M(.?)E4X=/P(./4$'O7Y85]9_L'^.7AU+7_",\G[J:,:C;*3P'4A) /<@H?\
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MS.S' 4 =2214%?4G[$?PK36M>O/&NH0![;3&^SV(<<&X(RS_ / %(Q[OGJ*
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MYY'K04C1HHHH&%%%% !1110 4456U'4+?2=/NKZ[E6"UMHFFFE;HB*"68^P
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MI8V#)(FE0!E(.000G!KK:!!1110,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDDB11L[L$11DLQP
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M(K]5/ _A6W\#^#]'T"UP8=/M4@W 8WL!\S_5FRWXT"1NT444%!1110 4444
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M (81\??]!?PW_P"!-Q_\8K[MHH'8^$O^&$?'W_07\-_^!-Q_\8H_X81\??\
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MRY#8]Q&)#^% 'PQ\;OB-+\4?B5J^MEV:S\S[/9*?X+="0G';/+'W8UP=%%!
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MBMH>CSQ^98+)]IO%;H88_F93_O8"_P# J\\KZZ_8'\, S^*O$4B<JL6GPO\
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MXRNHL2WS?8;)F7D1(<R,#Z,^%_[9FOC_ $'1;OQ)K=AI-C'YMY>SI;PIZLS
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M%?J!7Y?_  (_Y+-X+_["MO\ ^ABOU H*04444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\X_VMO^3@_%7_;I_P"DD-?HY7YQ_M;?\G!^*O\ MT_]
M)(:!,\@HHHH)"ON']@W_ ))SX@_["I_]$QU\/5]P_L&_\DY\0?\ 85/_ *)C
MH&CZ:HHHH*"BBB@ HHHH **** "BBB@#S?XW_!32OC-X9>UN%6VUBW5FL-0Q
M\T3_ -UO5"<9'XCD5^;FOZ#?>%]:O=)U*!K6_LY6AFB;^%@<'GN/0]^M?K77
MQM^W5\.8[/4-(\:6D6W[8?L%\0.#(JYB8^Y4,I]D6@3/DVBBB@DV_!OC#5?
M7B2RUS1KEK6_M7W*W\+#NC#NI'!'O7Z5_"+XH:=\7/!5IKMB!#*W[J[M=V6M
MY@!N0^HY!![@@^U?ES7M_P"R7\4)/ 'Q.MM.N)MFCZZRV<ZL?E64G]S)^#';
M]')[4#/T,HHHH*"BBB@#\V/VH/\ DO7B[_KO%_Z)CKRNO5/VH/\ DO7B[_KO
M%_Z)CKRN@@**** /NW]A'_DD6K_]AR;_ -)[>OHZOG']A'_DD6K_ /8<F_\
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M'^E S[9HHHH*"BBB@ HHHH **** "BBB@ HHHH *_+3XQ?\ )7/''_8=OO\
MTH>OU+K\M/C%_P E<\<?]AV^_P#2AZ!,X^BBB@D*_1#]CO\ Y(+HO_7>Z_\
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MPB_]I5^?=?I9^S-:+9? GPA&N,-:M)P,<O*[']6H&CT^BBB@H**** "BBB@
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M^[?7\ET2/S[%8NKBY\]5_P"2] HHHKZ$XPHHHH **** "BBB@ HHHH ****
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M!\_[XH)/MC2=+M]#TJRTZSC\JTLX4MX8_P"ZB*%4?D!5NBB@H**** "BBB@
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MG/BK_L%77_HEZ_*B@3"BBB@D*_6_1_\ D$6/_7!/_017Y(5^M^C_ /((L?\
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MM]_Z4/0)G'T444$A7Z(?L=_\D%T7_KO=?^CGK\[Z_1#]CO\ Y(+HO_7>Z_\
M1ST#1[711104%%%% !1110 5PGQW_P"2,^-/^P5<?^@&N[KA/CO_ ,D9\:?]
M@JX_] - 'Y?T444$!5S1O^0O8_\ 7=/_ $(53JYHW_(7L?\ KNG_ *$* /UO
MHHHH+"BBB@#\D-9_Y"]]_P!=W_\ 0C5.KFL_\A>^_P"N[_\ H1JG00%%%% '
MZ@? C_DC/@O_ +!5O_Z *[NN$^!'_)&?!?\ V"K?_P! %=W06%%%% !1110
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M8MFH:]()_F'(MUR(A^.6;Z,*"3Z HHHH*"BBB@ HHHH **** "BBB@ HHHH
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M]%%%!84444 ?DAK/_(7OO^N[_P#H1JG5S6?^0O??]=W_ /0C5.@@**** /U
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M^#O^O%?_ $(UZ/06%>9?M+6)U'X%^+X@N[;:+-C;G[DB/G_QVO3:P_'6A_\
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MJ/EO^)=9%AVX:5A_XXH/LPKZ[H!!1110,**** "BBB@ HHHH **** "BBB@
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ME_\  C_DLW@O_L*V_P#Z&*_4"@I!1110,**** "BBB@ HHHH **** "BBB@
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MRL&'Z@5^L'A_6K?Q)H.G:M:-NM;ZWCN8C_LNH8?H:"D:%%%% PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"11\4_]?T7_HNOJ:OEG]@?_D4?%/\ U_1?^BZ^IJ"PHHHH **** "BBB@
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M]/GU;4+:QM8S+<W,JPQ1KU9V("C\217ZJ> _"D'@;P;HV@6Y!CT^U2 L/XV
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ML?POJ5ZW;[=-';C_ ,=\ROBFB@+GO_C#]M/Q[XBCDATP67AV!N UI%YDV/\
M??(_$**\.UC6M0\0:A+?:I?7&HWLG+W%U*TDC?5F)-4:VM#\&>(/$S*ND:'J
M.J%NGV.UDE'_ (Z#0!BT5[9X7_8_^)'B-D:?3+?0X&_Y:ZE<*IQ_N)N;\P*]
MP\$_L*^']-\N?Q/K-UK4HP3:V@^SP^ZD\NP]P5H ^-O#_AO5?%FIQZ=HVGW&
MIWTGW8;6,NWU..@]SP*^MO@M^Q;%820:OX^:.YF7#QZ+ VZ-3_TV<?>_W5X]
M21Q7TMX4\$Z#X&T\66@:3:Z5;?Q+;Q@%_=FZL?<DFMR@=B.WMXK6".""-(88
MU")'&H554#   X  J2BB@84444 %%%% 'YL?M0?\EZ\7?]=XO_1,=>5UZI^U
M!_R7KQ=_UWB_]$QUY700%%%% 'W;^PC_ ,DBU?\ [#DW_I/;U]'5\X_L(_\
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M)/\ E^TS-Q#CU.T;E'^\HKS1E*L0000<$&@D]S^&/[7OC/P''%9ZDR^*-+3
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MHA^QW_R071?^N]U_Z.>OSOK]$/V._P#D@NB_]=[K_P!'/0-'M=%%%!04444
M%%%% !7"?'?_ )(SXT_[!5Q_Z :[NN$^._\ R1GQI_V"KC_T T ?E_11100%
M7-&_Y"]C_P!=T_\ 0A5.KFC?\A>Q_P"NZ?\ H0H _6^BBB@L**** /R0UG_D
M+WW_ %W?_P!"-4ZN:S_R%[[_ *[O_P"A&J=! 4444 ?J!\"/^2,^"_\ L%6_
M_H KNZX3X$?\D9\%_P#8*M__ $ 5W=!84444 %%%% !1110!XI^V)_R076O^
MN]K_ .CDK\[Z_1#]L3_D@NM?]=[7_P!')7YWT$L****!'8?!W_DKG@?_ +#M
MC_Z4)7ZEU^6GP=_Y*YX'_P"P[8_^E"5^I=!2"BBB@84444 <[X]\!:-\2?#-
MSH>N6PN+.895AQ)"XZ2(>S#_ !!R"17YX_&;X$:_\&]6*7D;7NC2MBUU2%"(
MY/16'\#_ .R?P)K],*J:KI-EKFG7%AJ-K#?65PNR6WN$#HZ^A!X- C\CZ*^Q
MOBM^P_%=23ZAX$O5M6)+'2;YSL^D<O)'L&S_ +PKY9\7> ?$7@.^^R>(-&N]
M*FSA3<1D(_NCCY6'NI- CK/@O\>=?^"^I.;';?Z/<,&NM+F8A'/3<A_@?'&1
MUXR#@8^X/AU^T=X&^)$,2VFKQ:;J+#G3]280RAO1<G:__ 2?PK\TZ* /UZ!R
M,CD4M?E'HOC[Q/X<C5-*\1:MIL:\!+2]EB7Z85@*VW^.GQ#D1E/C77 &&#B^
MD!_,'B@=S]/;BXBM87EFD2&)!EI)&"JH]237B/Q0_:X\&> [>6WTFY3Q1K R
MJP6+Y@0^KR_=Q[+N/TZU\%ZUXJUKQ(P;5]8O]48'(-[=/,?_ !XFLJ@5SJ?B
M)\2==^*7B"36->N_/G(VQ0H-L4"9R$1>P_4]237+45W?P^^"/C/XFS)_8FBS
MO9L<'4+@>5;*/7>W#8]%R?:@1PE?0W[/7[+-_P#$2:VU[Q+%+IWA@$21PL"L
MM^.H"]UC/]_N/N]=P]O^$/['?AWP/)#J7B.1/$NL)AEC=,6D+>R'[Y]VX_V0
M:^A0,# X%!5B#3]/MM)L;>RLK>.UM+=!'%!"H5$4# 4 = !5BBB@84444 %%
M%% 'Y.>,O^1NUS_K^G_]&-6/6QXR_P"1NUS_ *_I_P#T8U8]! 4444 ?II^S
MG_R0_P '?]>*_P#H1KT>O./V<_\ DA_@[_KQ7_T(UZ/06%%%% !1110!\H_M
M(_LGMK4]UXI\$VRB]?,E[H\:@"8\DR1>C'NG?J.>#\;30R6LTD,T;131L4>.
M12K*P.""#T(-?KO7E'Q?_9P\*_%U7NKB$Z3KN,+JEFHW-Z"1>D@Z=<'C (H%
M8_-NK>E:K>:'J5MJ&GW,EG>VT@EAGA8JZ,#D$&O4_B3^R[XY^'4DLW]G-KNE
M+DB^TM3( OJ\?WDXZG&/<UY&RE6((((."#02?:7P=_;4TW4K:#3/':_V=?J-
MHU:&,M!-[NBC*,?4 KU/R]*^E]%\0:9XDLEO-)U&UU.T;I-:3+*OYJ:_)2K>
MGZI>:1<K<6%W/97"]);>1HW'X@YH'<_7"BORZM?C9\0+.(1Q>--=V#H&U"5L
M>PRQXJKJ?Q9\;:RA2]\7:W<QG@QOJ$NS_OG=B@=S](_&WQ4\)_#NW>77]=M+
M!U&1;F3?.W^[&N6/Y8KXV^/'[6FI?$>WN="\.12Z/X=D^2:1R!<W:]PV.$0_
MW023W."17SX[M([.[%F8Y+,<DGUIE KA15[1]#U'Q#?I9:787.I7DGW;>UB:
M1S_P%037T;\+_P!B77=>,-[XQNO[!L3AOL,!62Z<>A/*Q_\ CQ]A0!X1X#^'
M^N_$K7HM(T"Q>\NGY=ND<*]W=NBK_P#J&3Q7Z%? WX%Z3\%] ,4.V]UNY4?;
M=2*X+]]B?W4'IWZGMCK/!/@'0?AWHJ:7X?TV+3[4<ML&7D;^\['EC[DUT- P
MHHHH&%%%% !1110 5\Q_M+?LL#QE)<>*?!]O'%KAR]YIRX5;P]W3L)/4'ANO
M7[WTY10!^1=W9SZ?=36UU#);7,+%)(9D*.C X((/((/:H*_2WXN?L]^%/B]"
M9M0MVL-85=L>J68"R^P<='7V/([$5\>?$C]DSQSX#DFGL[/_ (272UY%UIJE
MI /]N'[P/^[N ]:"3Q6M;PUXIU?P;JT6IZ)J-QIE_%]V:W<J<>A[,#W!R#Z5
MFRPO!(\<J-'(IVLC#!!]"*CH$?57@7]NS5+&&.W\6:''J@'!O=/<0R$>IC.5
M8_0J/:O8M#_;(^&6K*OVC4[S2';^"^LI"<^A,8<#\\5^>=% [GZ8Q?M(?#.:
M,.OC'3PK=F+J?R*YJO>_M/?"_3P3+XNM6XS^YAFE[X_@0U^:U% 7/OG7/VW/
MA[IJM]ACU75W_A^SVPC4_4R,I _"O+_%/[>>M76^/P]X;L]/7H)K^5KAOKM7
M8 ?Q-?+^GZ?=:M=QVME;37ES(<)#;QEW8^@4#)KW'X=?L<^-_&#17&L1IX6T
MYL$O>C=<$?[,(.0?]\K0!Y1X\^(&N?$K7FUGQ!=B\OC&(@RQ+&%0$D* H P,
MGWYKG*]5_:.^&>E?"7QU::#I#SRP#3HII)KEPSR2,SAF.  /NC@#M7E5 !11
M10(^U?V!_P#D4?%/_7]%_P"BZ^IJ^6?V!_\ D4?%/_7]%_Z+KZFH+"BBB@ H
MHHH **** "BBB@#X]_;G^&?ES:7XXLX@%DQ87^T<[@"8G/X!E)]D%?(U?JWX
M^\'VGC_P;J_A^] \B_@:+>1GRWZHX]U8*P^E?EIKVB7?AK6[_2;^/RKVQG>W
MF3T=6*G![C(ZT$LSZ**WO OA.Z\=>,-(T"SXGU"X6$-C.Q2?F<^RJ"Q]A0(^
MS?V)/AW_ ,([X!N_$]U'MO-;DQ#N'*V\9(7Z;GWGW 4U](51T71[7P_H]CI=
MC'Y5G90);PQ_W410JC\A5Z@L**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'G'Q6^ OA?XQ76GW.NB\CN+)'CCDLY1&65B#ALJ<@$<?4UP?_##_ ,._
M^>^M_P#@6G_QNOH.B@#Y\_X8?^'?_/?6_P#P+3_XW1_PP_\ #O\ Y[ZW_P"!
M:?\ QNOH.B@#A/A3\&?#OP=L]0M] %RWVZ19)I;N0.YV@A5R%' RW_?1KNZ*
M* "BBB@ HHHH **** "BBB@ HHHH \Q^*?[/?A?XP:Q::EKLFH)<6L'V=!:3
MJB[=Q;D%3SEC7%?\,/\ P[_Y[ZW_ .!:?_&Z^@Z* /GS_AA_X=_\]];_ / M
M/_C='_##_P ._P#GOK?_ (%I_P#&Z^@Z* /-?A7\ ?#/P=U"^O-!DOWFO(EA
MD^V3*XV@Y&,*.<UZ5110 4444 <U\0_ &F?$SPK<^']7:X6PN&1W-LX1\HP8
M8)![@=J\A_X8?^'?_/?6_P#P+3_XW7T'10!\^?\ ##_P[_Y[ZW_X%I_\;H_X
M8?\ AW_SWUO_ ,"T_P#C=?0=% 'B/A;]D/P-X0\1Z;K=C-JQO-/G2XA$URC)
MN4Y&1L&1^->W444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY1XZ_9D\#?$3Q/=Z_J]K>'4KH()G@NF16VHJ*<=OE4#CTKU>B@#PG_AB[X:_
M\^NI?^!K?X4?\,7?#7_GUU+_ ,#6_P *]VHH \)_X8N^&O\ SZZE_P"!K?X4
M?\,7?#7_ )]=2_\  UO\*]VHH \ F_8D^',DA96UB$?W4O%Q^J$U'_PP_P##
MO_GOK?\ X%I_\;KZ#HH ^?/^&'_AW_SWUO\ \"T_^-T?\,/_  [_ .>^M_\
M@6G_ ,;KZ#HH ^?5_8A^'88$S:T1GH;M.?\ R'5S_AB[X:_\^NI?^!K?X5[M
M10!XO;?L?_"V!E+Z#/<8&")+^<9]_E<5M:?^S/\ #'32IA\(63[<8^T/)-T_
MWV.:].HH YO2?AOX2T':=.\,:/8LO1K>PB1NW.0N2>!^5=&!@8' I:* "BBB
M@ HHHH **** "BBB@ HHHH \9\<?LH^"OB!XJU#Q!J<NJK?WS*\HM[E53(4*
M, H<<*.]87_##_P[_P">^M_^!:?_ !NOH.B@#Y\_X8?^'?\ SWUO_P "T_\
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M]_[H8*?Q':O8Z*!G.^'_ (=^%_"A4Z-X=TO3'7_EI:VD:/\ BP&3^)KHJ**
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M_&Z^@Z* /GS_ (8?^'?_ #WUO_P+3_XW1_PP_P##O_GOK?\ X%I_\;KZ#HH
MQO!_A6R\$>&=.T+3C*UE8Q"&(S,&?;DGD@#)Y]*V:** "BBB@ HHHH ****
M"N,\8?!SP5X\,C:YX;L+R>3[URL?E3G_ +:)AOUKLZ* /G#Q!^PQX*U!FDTO
M4]6TASTC,B3Q#\&7=_X]7#:C^P+?(Y-AXRMYESP+BP:,@?4.V>U?9%% CX?;
M]@WQ;N.WQ#HI7/!/G _^@5);_L%^*&8^?XDTB-<<&-97/ZJ*^W** L?(VE_L
M!Q*P;4O&;NO>.UT\*?\ OII#_*O1/#7[&?PXT%D>[M;[79%YSJ%T0N?]V,(,
M>QS7NM% &3X?\*Z-X3L_LFBZ59Z3;]X[.!8@?<X')]S6M110,**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110!\]^)%"^(M54=!=R@?]]FLVM?Q< /%&JX&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW8:/#U,=JK7,WT/W5'U#&@#YCKV'X._LR^*?BM-#=R0MHGA\X+:E=1G,B_\
M3)."Y]^%]^U?7GP]_99\ _#^2*Y733K>HI@B[U8B;:?58\!!ST.W(]:]= P,
M#@4#L<M\.?AIH/PK\.QZ/H-KY,/WI9Y#NEN'Q@O(W<_D!T  KJJ**!A1110
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M44 %%%% !1110 4444 %%%% 'A_Q(4KXSOR1PWED?]^UKF:ZSXGH5\77!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46093741908880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 26,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vir Biotechnology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2730369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1800 Owens Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">906-4324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001706431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNAS', window );">NASDAQ - ALL MARKETS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNAS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNAS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  B@EI:4VEK*X@$  "%$@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+68;6_R-A2&_XJ53=,FE9($RDL'2)3"AOK&"NLC;=H'DQBPFMAY;*>4?[_C
M0!.V)YRP2OM"XB3GYHI]?)_8O:U4KWK#F"'O<21TW]D8DUS7ZSK8L)CJ2YDP
M 7=64L740%.MZSI1C(994!S5?==MU6/*A3/H9==F:M"3J8FX8#-%=!K'5.UN
M6"2W?<=S/BX\\_7&V OU02^A:S9GYO=DIJ!5SU5"'C.AN11$L57?&7K7-W[;
M!F1/O'"VU4?GQ+[*4LI7VYB&?<>U1"QB@;$2% YO;,2BR"H!Q]>#J)/_IPT\
M/O]0GV0O#R^SI)J-9/2%AV;3=SH."=F*II%YEMM?V>&%KJQ>(".=_9+M_MEF
MTR%!JHV,#\% $'.Q/]+W0T<<!33\$P'^(<#/N/=_E%'>4D,'/26W1-FG0<V>
M9*^:10,<%W94YD;!70YQ9C"2;TSUZ@:D[(5Z< B[V8?Y)\(F;'E)_-8%\5W_
MZI_A=2#(,?P<P\_T&B?T;F60PE@;,A7[3+,C]N<]/$6FAL7ZKS+$O62S7-*F
M\[5.:,#Z#N2K9NJ-.8,?OO-:[L\(<",';F#J!?!BE[ R.#R\4[M#()HY1/,\
MB!E37(9D+$("65#*@ROEXUDUH%<YVA4J.!:&FQUY9FNNC:+ ^$CC4C!<YX4K
M<L.E8<%&R$BN=Q>0(L$E0MC*"5OG$(*:5(E46<I=D+F!_B-2D9%,A5$[.(:E
MV+CX[1@A;.>$[7,()SQBY#&-E^43%==P7:_6Z+J=!L+3R7DZY_ LZ#N9AI!V
M?,6#_4P]38<K=KR:WVZXC587P>OF>-US\(9A"--=7WR<D,Q%GD3I*.**7L=U
MR=,6:A#DA0*+12@]MW!<]_.<BZTL=6-<<IYRR-JNZV* 1R7!^T^ (]N"*;&0
M6U$*A\O-J2 3L(" ZT!B@$6Q\%!K_P8PG[0S)=^X"$J'ND)S-,30BK+@X<;^
M;[29U(9&Y ^>G'22"L5NT[OJ8&Q%M?!PD\_&<0C?;J=1< $@P4"*VN#AIGXO
M ^B3V48*S-@J1+INJ]9L^$V,J*@%'N[77Q0WA@GHF#A.Q<'6="D5+K2BD688
M4F'^'N[<<QGQ@!LNUN0!TEMQ&I7RX"J5/(7Y>[A7SQ2K!= ]#.;7_LN'B9 I
M\K1:G1@_7*^2K/!]#[?I;\BF6J= 5@F(RU8!^H7C^[@]+[B!$BY7Q/-_7/Y$
MYBQ((=]VI=^TN)+-3ZBWL"P(7B_(]^ZE"P6>)%21-QJE*&UA_S[NUPM%0YMU
M\UV\E*4Y5R'P,GW&0([6!&?9_#AF:FV!?@$%L[%S-*&BO/=PP<H1+6S>QTUY
M"'D69KDVB>BZ% 47J$0I7-W'3?G02R. 4>"J4\CY=W+'ROL'E[+)U'9;S8:'
MD14V[^,._3B<WPY_(S4RO+\G#\/GN_%B7DJ%RGQR(><7WN^W_H>U)UH&/LM<
M% >_HC@<+(2,WX,-%6MV<GE5(;0?HS*F^M&F@MV@>:!V%FH2L14HN9=M&#6U
MW_/8-XQ,LGV&I31&QMGIAE%P8/L W%])6,8=&G;K(M]Y&OP-4$L#!!0    (
M "*"6EJ?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_
M8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'
M=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;
M<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQ
MMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!I
MK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;
M.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7
M)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97
MHA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B
M<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;
M"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R
M%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,3
M1S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?
M^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WB
MDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7X
MC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]7
M4_P$4$L#!!0    ( "*"6EJ7BKL<P    !,"   +    7W)E;',O+G)E;'.=
MDKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<
M'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X9
M9K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.5
M6QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,
M<6*T_C6"R0_L?@!02P,$%     @ (H):6JK$(A8S 0  (@(   \   !X;"]W
M;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%
MC:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*
M0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,Z
ME._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8
M,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]
MC.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF
M*9ZC#GA3#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\
MGN4/4$L#!!0    ( "*"6EHD'INBK0   /@!   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*
MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L
MXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5
M&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFN
MWPQP>'3^ 5!+ P04    "  B@EI:99!YDAD!  #/ P  $P   %M#;VYT96YT
M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;
M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:
MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC
M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "*"6EH'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ (H):6C2@S*_O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ (H):6IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  B
M@EI:4VEK*X@$  "%$@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ (H):6I^@&_"Q @  X@P   T
M         ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  B@EI:EXJ[
M',     3 @  "P              @ &H#P  7W)E;',O+G)E;'-02P$"% ,4
M    "  B@EI:JL0B%C,!   B @  #P              @ &1$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ (H):6B0>FZ*M    ^ $  !H
M     ( !\1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ (H):6F60>9(9 0  SP,  !,              ( !UA(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vir-20250226.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="vir-20250226.htm">vir-20250226.htm</File>
    <File>vir-20250226.xsd</File>
    <File>vir-20250226_def.xml</File>
    <File>vir-20250226_lab.xml</File>
    <File>vir-20250226_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vir-20250226.htm": {
   "nsprefix": "vir",
   "nsuri": "http://www.vir.bio/20250226",
   "dts": {
    "inline": {
     "local": [
      "vir-20250226.htm"
     ]
    },
    "schema": {
     "local": [
      "vir-20250226.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "vir-20250226_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vir-20250226_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vir-20250226_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.vir.bio/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vir-20250226.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vir-20250226.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "exch_XNAS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2024",
     "localname": "XNAS",
     "presentation": [
      "http://www.vir.bio/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ - ALL MARKETS",
        "label": "NASDAQ - ALL MARKETS [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-25-008163-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-008163-xbrl.zip
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MX+,H9!_\.(@&[']C'L"2Z:L/L>NR/P0/D&A-]L'QN&?! N&=,':C<!))*T
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MKF+!N$QX?=X70<A^O[JI--IZFX:A/QJU&B(0A-4][!-&$I$2A(A)./TA>W"
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M+.IE#D"+P]JX?0]'2Y#@(@T)3Y52%9"L@- 0NXD!,F5XK&!OR",9H(8U9:<
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M9)_>_TXO__(3F"JLQJ[^26;N\#/83+AZSV?DZD(-IT*$@<HZ8 QU:V!TH-6
M\G=/OH2CV[/+\'@QM\H'9V:);5&X1H4K:MDKO NZ&1@1"U])3GL@R:4]R0C7
M#/K<.4,XJ%_% [OQA]S;6$VG5<Z-^<A_!T&V_+ZH=-$%7.$]4*M/N/O Q^&;
MYXQV+8]2K/Y2*9*>5R0MC!],<"-2^,>@)(19\& 8NQ%8)P*5EQC.E!^,)P,
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M!KW2G)V,1J#=CA+#B9"!2BFHR^C5 \J\N+E8H@-NF1Z?0STH B4FZD$2C5Y
MBM>W7\Y6)\7KVS- OQU;4C^ )U%]!'J3%* ;1 (@T4$4<PQ46SQQBB#9./"I
M1QYX_%JD!#"\N+F^.,XBXZ3#,DJ!<(CDB.TI2H6]3E%J%==5&/-7KYK+C-]&
M;0>&;YKN@.&9[$0CNV@#^EIY[.4/<'DJ7^A4GOO(6I-3!N? =C"D&(*"#CP2
M3YNW.!U%<6:*!,1#%OFND&X+.B9'7^[>'Y,-/P;-&M1GC%YK:);CUQ54.^BH
M6^/(_X[^;J!>="VQ<.S9,*5 AGP+I-"%#=^K(!R\#1^R/N6PH(,*#B<H$K9@
M1G%\C4^/B15#KZQ+)>)*,;^43*;]5,31KV^^5?Y]=_D5EFZVC5.&?)T,K32V
M2+'OUFG.G*,X$@Q*<:1P'$9B"+PZ\G_ N0<Z>Q@ E<FH$U$?T(=%LON[(Y.I
M@$LHUHTJ9ICXD:0F D,%OO#0=>6A5:@E4^&;2$0RJ(M938E!.)O:9*'V'*#R
M@]XD;CO*PY9_,HF7B4VUV=*Y\+AS(6?)3,0IYF>\)8;Z8V8+)G4YR,@X&D%]
MQ'(2?_5'D:1+>$<Z&S*SJ,K.[(04W/&4G?6\.607ETL2QS0F,/K*Z5$<*3M9
M2CGGS(O)S0QOY,+"2-VP$]*>5B?:P@48SS&X>%X&%U_*H9 _=:"&D3:&RD$O
M]JPDU(!N_LD@E&'"5.([Z_FNZS]4XE$2N/AR=G/QB5VCA_ \C5#)P)0B\5"
M4FBG*4IE%'%+443AV1A02N,E:>[8XYC+<:!H609YS@E,6N/UY<?*U0=0%SIF
MXY2"/HO>YJX/VN%LZ)("D+/Q1QG5FQMC$W-";%:6FSW(,98P#GK<$D3V?>&Q
MHT_GX5G_F+F^<B;C%RJ;;]%[6!O$CO"W"KQ]/.FBEJ%7@:E=O2Q051Q2/S E
M]D,<(:?*IW"1G_^<=<<3\OL!=$O61?^0%ZEH)BH*PI)Y#IP]^(%K/SA@<DR'
M'("4AB+ W,LD UJE3S$_CD)\ U!],8!CP.Y$$#@4Z#BZ%O[(%:ER?"-&,>B[
M5OJLQCZ!&L/^ ?]H[(X[#UR&!KYPB\?'LC0%] *5G)6H+_FU$7-%K0FH#(<=
M *QR 8\E"L#6XIY;JFR;']HT7EMH<\>*W'4@4ELRS7:[2'T/)0M\&1:XT(9*
MXZ^QAXFB(.(HKRL7PKFXA.?[W &IF;H!W#&F?A+*;)6Q$4X7#H%I["9V1F:2
M8,0 _4B3-DE($CHD(3_/(^4"1PLP[I#W-A3&V_IHLM'=EQWX6V>=,!)#'FA&
MKD0K8AS^"I(L=P^.F* _97;/3(IX*JE2%2<9@HS?"+-[::B<5,U</X$_0N1C
MO-$^NPK_2-Q%1R^9>#Z?#=G;1PAJG]O?Z-D5"[>_URB(+:ES*6T9:&7[>Q]O
M?^/'#  NSU%QU/D#LUSSLDQJZK$L(E */GG#/EW]SKJ!SVT059Z(P>!SI?<W
MY5Q)5C3F+>#3Y,T@:]5U>5<EYV>YT!])$'WP04[*[)N-2Q3TVE[7*$RW*B@,
MF1^8RG8UY<28=#4/_)!<(9Y* ,8J;<QG)0//Q:$IQ6<V51P/QTRJ>.J(FU>5
MA&\L=]_EG2"S;IJ2$;X0(UR:\\4]#WB5A3DS"1$DF0R+(B*22- =]^"C@HZ(
MGQ?:2ZR"K-7#%!&6L;!MR+X,PU^XA^ !.0:,695_2F<6#\-X*,VFP'?)"965
M@O[N6%AI)M ]A3%262IZA]H^&6#?1B)0]INJ&L7#GM13*YJ3GOXDBFH+='NI
M]'_\ *1J@&PI-[:T1=(ZU#/T 'SBGBO&:ND;"];Z7@O6YVSS4\CB;*Q&I>)H
MJH5.B OC"$@+CO"L<=(#A32SZ982%M 0)8,PH_TWJN^NH.E9H4KO-"6,4E;E
MX-ASY<=(>*'0X!?+C=-H?SP"80C;5U^SI$8$0_U8^,0]O^<P%RC4DQ'@?B#(
M<ZS]\E/=5!78_\-#F.[;K^?CP!.JW'K1Z:*-R4.087%)+3:C>?Z5+U&6NBB'
M@]P%'.:*_1.O!*Y>I<A3%>YW,<Z5]B;0Q)"WXR7 V+0#!QEVBQMP5&GYA2//
M!<%EVC+^RRZGMGR5;5D6!6S?I#RC2-S\[@Q3.B&W94+*#V<(2 ?+9T/L:MA2
M0NIQ,NYADU>.F/K4!)U:M0E8EQ/DZT$G&T[(:*Y9!0-*-:1(NT^HK[15*4^M
M96:KC3H(R60I,N)'3#.;"=X,*,M,DC]V5P (U>K55KJ#A"^,N*R.'V)Z&="U
M8@CQ2-:Q,'24JBRD&7XA,FY!B_^YU:C6TAFB >C%#[($Q@7Q[/0<R7< WJ!0
M4UTMP2!):!HXP714W%0E>MW_""O"=Y.<$L4C<66*Y\K$$=31XR'H:3*A)2FR
M[Y(0;^Y-%L@-:I>QV-5)5-.GY;$)4I;U3R%4_PSZFYE20#ZO[&>]66VGWR0#
MAQQTMA&6*U)^+(Q3K[+IV6=.D)RJ95:-^5.UF[EOTF$I,JX.1II%M[1=C(K&
MP\$+L*V8'8"T\Y"60&A3^@"M4V,/ WP0E$,1)!\FA$^E6#+YEUN@"]GDMR'Y
MAH(K.S_TT?G9S?NSU*T\ZX@!.XBKG"Q-::'I09\"5=8?)H+#UHUE72I 9V*9
M89;0DB2F8E(RIKX"Q0RXC 8/80F82 [GS8]#EYQ1*&Z).9%>)U-B:D:-?;S]
M!SM+=8BDC,'%.$@O%%$2B%:@23J*V*(G D1? KXI-06T%R>@6 J,G_K9*4!(
M#C&9-0E<BUYX\%,P@=+@^1[85#TW%MY?/*FZ!3-^X/>!A\V6]D]S\E<>-ZZ7
M<>/MZFA89 ZTMV,1D"PCF&;&<]4=R9%K.?UB@B'75F7]"V>=+P+RXTY,:.2^
M6"  B+G;<8XGD@)208XU!M-CS%TT(1B5XF"$DWIBX6+DTY/>\V3!R[CAOI2Q
M@LD-D+9D9]/WN12;2VE#ANSH!JR>]NG[8Z+.'81\U?R)5;NP_5M*+8ALT(";
M53VA"Q3;CC5(5&307MN95HTOHMP@_32,?.M[19( )=)YH41Z:G)/*CJU3C;+
M,G*?70'H2(V-EE!= I'9HT/ :-1RD\TNQ:Q7.\\!C4:KD^,*"W?>-')/K;?S
M_+%.NX=,DL$4<(AYY/2Z/!.8@!_@*_0]3[BJO5<E==2(U'D3SE=RT@W N4[*
M\Y-E@#&$:20.@ E+P[!O^P#5DE EV*4Y>:AG.;9R'X'1Q<' Q9J1(,E'3>R_
MF?VG2%]CZUD^"G#A;"T!M] \].(>QU W53/)!U0C'8!%&CR<3H6@K D9N03-
MVHWEWC6RXPRS;6@I-UUCHBQKEAJR*MUW>NJ+3^^E+^K3^72))7TN)\Y03',M
MUECA7.>ERJ0]/&U-=P4UF<GT?Q[.(X2$AO=$,-S*%&*-?10>$*4\%6<V5AS)
MPM-[D9,1MQ]IEV?'NU)AD@6L*26,9L:*9AE5:T,./<4633UGHJXG(_1)*ER#
M4RX!R (AH>N=S*,SNY:Z^3S0T,&6-Q\7$F8[YX)[@I" ";I^TOEMU@$P"9!)
MAIFS2Z?Y!S4PI;3D%+S3C"MG0F<Q+>0[E9"3+ROILWDO5J\&WKVVJ)*@B#5\
M]KU^Y3-UO#F38NXJ$W/RK@<)P0LI\G;GXII8MHO+=FG9L])9MM61RTXD]4JL
MY B4J./Y%HJ9TW>6FD1(N5,#S?==Y2VCN03+&2:W*H^/"(94J:*Z][K)P;B-
MJH##V %)^,4)L:6OH]9@3NIQ"U=07[P"6?V$&:[H!4N.R=YX9;_1Z;[R )$[
ML\OE&AQ:PTI&N6[D>/0DU\T;/(_28,H]EVB0#H;P!+GA<7U5-G^U\XWYIIDS
MFR9MB)S9-KDH&/G11<4>/.*2%D9U3:G'4RF,OX84A8G&N>!+3D&$50/\493
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MDN_OGO?.SU5+)F\K7W:!YF-/GA<PJ#K_X%YF#13GGMO\H:$#DFL<&P[1AJ>
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M,VO-EUEL?:5A?R/X2ABC>W#$O;^_J;_)F#Q=8W)28SK=VY*,ES[:F7G4&/W
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MO'_+^L;@IQ6_5XG3=ORO0<(W.EISE]'F4L(O1$U+!V9LE!)^%_%_S_=>40I
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MS3Z+T?>B'X7W3B L *;&$K"R&^$6EOQAZ<O(/W 1Y"O1OAJQ9<"4(S]T:*B
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M@_R94PB9>*P(O\)RA=3#G!UV_H+.GNLXK)]&9YN9$X-?C!DL,<77#$87Q@)
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M^LZ$>ASJ7E  ^0EL-!AJ_V&)KK]^B5ZQA<PROMP69ZM&(7I=D^B-_I*E/-?
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M\'DPGEJ>1:)=P,%2,4J,LX(8'R2 E,D[-@D)=\QNU?@P'1)/EW;3Z6*?-GV
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M97@Y.3%E87)N:6YG<W(N:'1M4$L! A0#%     @ (H):6I:Y<DDZ#P  J6<
M !               ( ! 3(  '9I<BTR,#(U,#(R-BYH=&U02P$"% ,4
M"  B@EI:,Q4A27("  !;"   $               @ %I00  =FER+3(P,C4P
M,C(V+GAS9%!+ 0(4 Q0    ( "*"6EK2'@9 $0@  ,8[   4
M  "  0E$  !V:7(M,C R-3 R,C9?9&5F+GAM;%!+ 0(4 Q0    ( "*"6EH:
MS4">( P  /9H   4              "  4Q,  !V:7(M,C R-3 R,C9?;&%B
M+GAM;%!+ 0(4 Q0    ( "*"6EI@OH.UT0<  )4^   4              "
M 9Y8  !V:7(M,C R-3 R,C9?<')E+GAM;%!+!08     !@ & (X!  "A8
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>vir-20250226_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:exch="http://xbrl.sec.gov/exch/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vir-20250226.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNAS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001706431</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Vir Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39083</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">81-2730369</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1800 Owens Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">906-4324</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">VIR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
